4.5 Article

Higher homocysteine associated with thinner cortical gray matter in 803 participants from the Alzheimer's Disease Neuroimaging Initiative

Journal

NEUROBIOLOGY OF AGING
Volume 36, Issue -, Pages S203-S210

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2014.01.154

Keywords

Alzheimer's disease; MRI; Cortical; Gray matter; Atrophy; Thickness; Volume; Surface area; Brain structure; Homocysteine; Folate; Vitamin B

Funding

  1. National Defense Science and Engineering Graduate (NDSEG) Fellowship [32 CFR 168a]
  2. U.S. Department of Defense
  3. Air Force Office of Scientific Research
  4. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  5. National Institute on Aging
  6. National Institute of Biomedical Imaging and Bioengineering
  7. Abbott
  8. AstraZeneca AB
  9. Bayer Schering Pharma AG
  10. Bristol-Myers Squibb
  11. Eisai Global Clinical Development
  12. Elan Corporation
  13. Genentech
  14. GE Healthcare
  15. GlaxoSmithKline
  16. Innogenetics
  17. Johnson and Johnson
  18. Eli Lilly and Company
  19. Medpace, Inc
  20. Merck and Co, Inc
  21. Novartis AG
  22. Pfizer
  23. F. Hoffman-La Roche
  24. Schering-Plough
  25. Synarc, Inc
  26. Wyeth
  27. Alzheimer's Association and Alzheimer Drug Discovery Foundation
  28. Northern California Institute for Research and Education
  29. National Institutes of Health [P30 AG010129, K01 AG030514]
  30. Dana Foundation
  31. U.S. Food and Drug Administration

Ask authors/readers for more resources

A significant portion of our risk for dementia in old age is associated with lifestyle factors (diet, exercise, and cardiovascular health) that are modifiable, at least in principle. One such risk factor, high-homocysteine levels in the blood, is known to increase risk for Alzheimer's disease and vascular disorders. Here, we set out to understand how homocysteine levels relate to 3D surface-based maps of cortical gray matter distribution (thickness, volume, and surface area) computed from brain magnetic resonance imaging in 803 elderly subjects from the Alzheimer's Disease Neuroimaging Initiative data set. Individuals with higher plasma levels of homocysteine had lower gray matter thickness in bilateral frontal, parietal, occipital, and right temporal regions and lower gray matter volumes in left frontal, parietal, temporal, and occipital regions, after controlling for diagnosis, age, and sex and after correcting for multiple comparisons. No significant within-group associations were found in cognitively healthy people, patients with mild cognitive impairment, or patients with Alzheimer's disease. These regional differences in gray matter structure may be useful biomarkers to assess the effectiveness of interventions, such as vitamin B supplements, that aim to prevent homocysteine-related brain atrophy by normalizing homocysteine levels. (C) 2015 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available